{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:12:33Z","timestamp":1769595153993,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.3816\/clml.2010.n.079","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T21:10:48Z","timestamp":1287695448000},"page":"452-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma"],"prefix":"10.3816","volume":"10","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Van der Jagt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Tremmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.079_bib1","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.079_bib2","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib3","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"A phase III study of rituximab plus CVP versus CVP alone in patients with previously untreated advanced follicular lymphoma: updated results with 53 months\u2019 median follow-up and analysis of outcomes according to baseline prognostic factors","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib4","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 toxitumomab (Bexxar) in B-cell lymphoma progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.079_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.079_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab refractory and alkylator-refractory, indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib9","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.V114.22.2681.2681","article-title":"Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin's lymphoma: a pooled analysis","volume":"114","author":"Cheson","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.079_bib11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood.V114.22.3694.3694","article-title":"Bendamustine is highly effective for relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (B-NHL) and mantle cell lymphoma (MCL): final results of a Japanese multicenter phase II study","volume":"114","author":"Ogura","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.079_bib12","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin's lymphoma treated with Tositumomab and I 131 Tositumomab (Bexxar (R))","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.079_bib13","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogeneous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CLML.2010.n.079_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLML.2010.n.002","article-title":"Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin's lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel","volume":"10","author":"Cheson","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.3816\/CLML.2010.n.079_bib16","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib17","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: a phase II multicenter study","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.079_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.079_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.V112.11.1003.1003","article-title":"FLIPI score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [R]","volume":"112","author":"Czuczman","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.079_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.V114.22.1714.1714","article-title":"A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma","volume":"114","author":"Fowler","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.079_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V114.22.924.924","article-title":"Bendamustine, bortezomib and rituximab in patients (pts) with relapsed\/refractory indolent and mantle cell non-Hodgkin's lymphoma (NHL): a multicenter phase II clinical trial","volume":"114","author":"Friedberg","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:46Z","timestamp":1761870166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S2152265011700453"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.079","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}